Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.50 |
| ▸ | BCHE | P06276 | 10/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8409986 | 0.89 | ACHE (0.61) | ACHEBCHEPRMT6HRH2 | |
| Oxalic Acid SCHEMBL5111815 | 0.82 | ACHE (0.50) | ACHEBCHEPRMT6SMYD3 | |
| SCHEMBL2458150 | 0.78 | ACHE (0.74) | ACHEBCHEPRMT6 | |
| SCHEMBL2218079 | 0.74 | TDP1 (0.60) | ACHEBCHESMYD3 | |
| SCHEMBL8610492 | 0.72 | ACHE (0.61) | ACHEBCHEPRMT6 | |
| SCHEMBL1733144 | 0.72 | ACHE (0.61) | ACHEBCHEPRMT6 | |
| SCHEMBL9838312 | 0.71 | — | — | |
| SCHEMBL2511640 | 0.69 | ACHE (0.52) | ACHEBCHEPRMT6HRH2 | |
| SCHEMBL3927787 | 0.69 | SMYD3 (0.54) | ACHEBCHEPRMT6SMYD3 | |
| SCHEMBL8007208 | 0.69 | ACHE (0.55) | ACHEBCHEPRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0150073-B1 | 3,4-DISUBSTITUTED-1,2,5-OXADIAZOLES HAVING HISTAMINE H2-RECEPTOR ANTAGONIST ACTIVITY | Bristol-Myers Squibb Company (US) | 1990-09-26 | — | — | EP | disclosed |
| EP-0150073-A1 | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2-receptor antagonist activity | Bristol-Myers Squibb Company (US) | 1985-07-31 | — | — | EP | disclosed |
| US-4515806-A | ANTIULCER, ANTISECRETORY | INKE, S.A. (ES) | 1985-05-07 | — | — | US | disclosed |
| US-4507485-A | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity | BRISTOL-MYERS COMPANY (US) | 1985-03-26 | — | — | US | disclosed |
| US-4497961-A | Process for the preparation of ranitidine | GLAXO GROUP LIMITED (GB) | 1985-02-05 | — | — | US | disclosed |
| EP-0059082-B1 | PROCESS FOR THE PREPARATION OF A FURAN DERIVATIVE | GLAXO GROUP LIMITED (GB) | 1985-01-30 | — | — | EP | disclosed |
| US-4413135-A | Intermediates in the preparation of ranitidine | GLAXO GROUP LIMITED (GB) | 1983-11-01 | — | — | US | disclosed |
| US-4399293-A | Process for the preparation of a furan derivative | GLAXO GROUP LIMITED (GB) | 1983-08-16 | — | — | US | disclosed |
| EP-0059082-A1 | Process for the preparation of a furan derivative | GLAXO GROUP LIMITED (GB) | 1982-09-01 | — | — | EP | disclosed |